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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the fourth most common cause ヱΒ 
of end-stage renal disease. The disease course can be highly variable and treatment options ヱΓ 
are limited. To identify new therapeutic targets and prognostic biomarkers of disease, we ヲヰ 
conducted parallel discovery microarray profiling in normal and diseased human PKD1 ヲヱ 
cystic kidney cells. A total of 1515 genes and 5 miRNA were differentially expressed by ヲヲ 
more than two-fold in PKD1 cells. Functional enrichment analysis identified 30 dysregulated ヲン 
signalling pathways including the epidermal growth factor (EGF) receptor pathway. In this ヲヴ 
paper, we report that the EGF/ErbB family receptor, ErbB4, is a major factor driving cyst ヲヵ 
growth in ADPKD. Expression of ErbB4 in vivo was increased in human ADPKD and Pkd1 ヲヶ 
cystic kidneys, both transcriptionally and post-transcriptionally by mir-193b-3p. Ligand-ヲΑ 
induced activation of ErbB4 drives cystic proliferation and expansion suggesting a ヲΒ 
pathogenic role in cystogenesis. Our results implicate ErbB4 activation as functionally ヲΓ 
relevant in ADPKD, both as a marker of disease activity and as a new therapeutic target in ンヰ 
this major kidney disease. ンヱ 
 ンヲ 
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Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic ヴヰ 
disease affecting the kidney (incidence 1 in 1,000) and is caused by mutations in two genes, ヴヱ 
PKD1 (85-90%) or PKD2 (10-15%) (21). Around 10% of patients requiring renal ヴヲ 
replacement therapy have ADPKD making it a major economic, medical and psychosocial ヴン 
burden worldwide (21). Recent studies have confirmed strong genic and allelic influences on ヴヴ 
the age of end-stage renal disease (ESRD) (4). However, the course of disease can be highly ヴヵ 
variable with evidence of intra-familial variability indicating the likely influence of other ヴヶ 
genetic factors (modifying genes, microRNAs), epigenetic factors and environmental ヴΑ 
triggers.  ヴΒ 
The recent approval of the vasopressin type 2 receptor antagonist, tolvaptan, for ADPKD ヴΓ 
patients with mild to moderate chronic kidney disease (eGFR >30ml/min/1.73m2) and ヵヰ 
evidence of rapid disease progression represents a step-change in the management of this ヵヱ 
condition (8, 16). However, the drug is only moderately effective and has significant side-ヵヲ 
effects including a risk of liver toxicity, limiting its use and requiring frequent monitoring.  ヵン 
There is therefore a need to develop more effective and safer drugs, which could also be used ヵヴ 
in combination. In addition, the identification of new prognostic biomarkers would be a ヵヵ 
major advance, especially in the early stages of disease, before significant increases in cystic ヵヶ 
burden occur (as measured by total kidney volume).  ヵΑ 
To identify new therapeutic targets and prognostic biomarkers in ADPKD, we conducted ヵΒ 
parallel microarray discovery profiling in normal and diseased human PKD1 cystic kidney ヵΓ 
cells, generated from nephrectomy tissue. Our results identify 30 dysregulated signalling ヶヰ 
pathways when genes altered by at least 2-fold in abundance are analysed. Among these was ヶヱ 
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the EGF receptor signalling pathway, several members of which have been previously ヶヲ 
implicated in PKD pathogenesis. In this paper, we report that expression and activation of the ヶン 
EGF-related receptor, ErbB4, is increased in human and mouse models and that this drives ヶヴ 
cyst proliferation and expansion in vitro. We also demonstrate that ErbB4 is a target for mir-ヶヵ 
193b-3p, a novel finding. Finally, we show that urine exosome ErbB4 correlates significantly ヶヶ 
with the rate of renal disease progression (eGFR slope), providing additional prognostic value ヶΑ 
to mean kidney length (measured by ultrasound) in ROC analysis. These results indicate that ヶΒ 
activation of the ErbB4 pathway is functionally relevant in ADPKD pathogenesis, reflects ヶΓ 
disease activity and represents a new potential therapeutic target in this disease. Αヰ 
  Αヱ 
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Materials and Methods Αヲ 
Materials Αン 
All chemicals were purchased from Sigma Chemical (Poole, Dorset, United Kingdom), Αヴ 
unless otherwise stated. Αヵ 
 Αヶ 
Cell Lines ΑΑ 
Non-cystic (UCL93, RFH) and cystic (OX161, OX938, SKI-001, SKI-002) epithelial cells ΑΒ 
were immortalised from primary cultures of tubular cells isolated from normal and ADPKD ΑΓ 
human kidneys removed for clinical indications as previously described (24). SKI-002 cells Βヰ 
were found to carry germline (IVS25-3C>G) and somatic (2312_2324del) PKD1 mutations Βヱ 
both of which are predicted to result in premature protein truncation. Βヲ 
Cells were grown in Dulbecco’s Modified Eagles Medium-Ham’s 12 (DMEM-F12, Βン 
Invitrogen) supplemented with 1% L-Glutamine (Invitrogen), 5% NuSerum (Becton Βヴ 
Dickinson) and 1% antibiotic/antimycotic solution (Invitrogen) at 33°C/5% CO2. HEK-293 Βヵ 
cells and control CL8 and CL11 kidney epithelial cells were cultured in Dulbecco’s Modified Βヶ 
Eagles Medium-Ham’s 12 (DMEM-F12, Invitrogen) supplemented with 1% L-Glutamine ΒΑ 
(Invitrogen), 10% FCS and 1% antibiotic/antimycotic solution (Invitrogen) at 37°C/5% CO2. ΒΒ 
 ΒΓ 
Transfections Γヰ 
Cells were transfected with a plasmid expressing the JM-A CYT-1 isoform of ErbB4 Γヱ 
(Addgene plasmid #29527, pcDNA3.1-ErbB4) using Lipofectamine 2000 for 48h prior to the Γヲ 
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cell proliferation assays. In some experiments, cells were transfected with negative control or Γン 
mir-193b-3p miRNA mimic (Life Technologies) using RNAiMax (Life Technologies). Γヴ 
 Γヵ 
RNA extraction and microarray Γヶ 
Total RNA was extracted from cells using Trizol according to the manufacturer’s protocol ΓΑ 
(Life Technologies). All human cells were maintained and RNA extracted between passages ΓΒ 
10-20. Prior to RNA extraction, cells were synchronised by serum starvation for 24h ΓΓ 
followed by reintroduction of serum for 24h in order to standardise the growth conditions ヱヰヰ 
between the different cell lines. RNA quality was determined using an Agilent 2100 ヱヰヱ 
BioAnalyser. Parallel mRNA and miRNA microarrays were carried out on Agilent human ヱヰヲ 
mRNA microarray (SurePrint G3 Human Gene Expression 8x60K v2 Microarray, one glass ヱヰン 
slide formatted with eight high-definition 60K arrays) or human miRNA microarray (Release ヱヰヴ 
19.0, 8x60K, one glass slide formatted with eight high-definition 60K arrays based on ヱヰヵ 
miRBase Release 19.0) respectively.  ヱヰヶ 
A guided workflow based on Agilent single colour expression data within Agilent ヱヰΑ 
GeneSpring GX software was used to identify differentially expressed mRNA and miRNA. ヱヰΒ 
Briefly the guided workflow carries out a thresholding of the signal values to 5 followed by ヱヰΓ 
log transformation. It then normalizes the data to the 75th percentile and performs baseline ヱヱヰ 
transformation to the median of all samples. Samples are then divided into experimental ヱヱヱ 
groups and entities filtered based on their flag values: P(present), M(marginal) and A(absent). ヱヱヲ 
Only entities having the present and marginal flags in at least 1 sample are displayed. ヱヱン 
Differential expression significance analysis is performed by unpaired T-test and p-values ヱヱヴ 
>0.05 were defined as significant. Fold change analysis is then used to identify genes with ヱヱヵ 
expression ratios or differences between ADPKD and control cells that are outside of a given ヱヱヶ 
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cutoff or threshold. Fold change gives the absolute ratio of normalized intensities (no log ヱヱΑ 
scale) between the average intensities of the samples grouped. The entities satisfying the ヱヱΒ 
significance analysis are passed on for the fold change analysis. All array files are available ヱヱΓ 
from the ABI ArrayExpress database (accession number(s) E-MTAB-4188, E-MTAB-4189) ヱヲヰ 
Pathway analysis was carried out using The PANTHER (Protein ANalysis THrough ヱヲヱ 
Evolutionary Relationships) classification system which was designed to classify proteins ヱヲヲ 
(and their genes) in order to facilitate high-throughput analysis. All genes which showed a >2 ヱヲン 
fold change in expression in ADPKD cell lines were mapped to PANTHER pathways which ヱヲヴ 
consists of over 177 primarily signalling pathways. Pathways which were statistically ヱヲヵ 
overrepresented (p>0.05) were then identified. ヱヲヶ 
 ヱヲΑ 
Quantitative PCR ヱヲΒ 
Relative ErbB4 and mir-193b-3p expression between control (n=4) and ADPKD (n=4) cells ヱヲΓ 
as well as in isolated exosomes purified from human urine samples was determined by ヱンヰ 
Taqman qPCR according to the manufacturer’s protocol (Life Technologies). Following ヱンヱ 
RNA extraction, cDNA was synthesised from ADPKD, normal cells and exosomes using ヱンヲ 
specific mir-193b-3p RT primers or a total RNA to cDNA kit (Life Technologies). Real time ヱンン 
PCR was carried out on an ABI7900 qPCR machine. Normalisation of expression was carried ヱンヴ 
out using specific primers to GAPDH or RNU44. Results presented are representative of 3 ヱンヵ 
separate experiments. Cre;Pkd1del2–11,lox  mice were generated as previously described (15). ヱンヶ 
RNA was extracted from 4-5 mouse kidneys at 3 months and 4 months after tamoxifen ヱンΑ 
treatment at post-natal day 40, retrotranscribed into cDNA and changes in ErbB4 and mir-ヱンΒ 
193b-3p expression determined. Analysis of gene and miRNA expression were carried out ヱンΓ 
using DataAssist v3.01 (Applied Biosystems) to calculate 1/〉Ct normalised expression ヱヴヰ 
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values for each cell line. Data was plotted in Graphpad Prism and p-values >0.05 (adjusted ヱヴヱ 
for Benjamini-Hochberg False Discovery Rate) were defined as significant. Relative ヱヴヲ 
quantification was also carried out using the comparative Ct (〉〉Ct) method to calculate fold ヱヴン 
changes in expression between control and ADPKD samples. ヱヴヴ 
 ヱヴヵ 
Small Interfering (siRNA) knockdown ヱヴヶ 
Isoform-specific siRNA to human ErbB4 was chemically synthesized by Cell Signalling ヱヴΑ 
Technology. A scrambled negative control siRNA (Silencer) was purchased from Ambion. ヱヴΒ 
Transfection of siRNA into cells was achieved using RNAiMax reagent (Life Technologies). ヱヴΓ 
Knockdown was confirmed by qPCR 48 h post-transfection. ヱヵヰ 
 ヱヵヱ 
Immunoblotting ヱヵヲ 
Total cell lysates were prepared and processed for immunoprecipitation and Western blotting ヱヵン 
as described previously (20). Cells were solubilized in detergent lysis buffer (50 mM Tris, ヱヵヴ 
0.14 M NaCl, 1% Triton X-100, and 0.5% NP40) supplemented with Complete protease ヱヵヵ 
inhibitors and PhosStop phosphatase inhibitors (Roche Diagnostics, Mannheim, Germany). ヱヵヶ 
Commercial antibodies against the C-terminus of ErbB4 (EP192Y), phosphoErbB4-Y1188 ヱヵΑ 
(EPR2271Y) (Abcam, UK), calnexin, pAKT, total AKT, pERK and total ERK (Cell ヱヵΒ 
Signalling, USA) were used for western blotting. ECL detection and quantification was ヱヵΓ 
carried out using a Biorad Chemidoc XRS+ system running Image Lab automated image ヱヶヰ 
capture and analysis software. All quantification was carried out on non-saturated bands as ヱヶヱ 






Archival nephrectomy sections were obtained from 6 ADPKD patients with known ヱヶヶ 
truncating PKD1 mutations and from 3 control patients (22). Mouse kidney tissue from ヱヶΑ 
Cre;Pkd1
del2–11,lox  mice were obtained at 1, 2, 3 and 4 months post tamoxifen treatment (n=3). ヱヶΒ 
Formalin-fixed paraffin sections were dewaxed and hydrated through graded ethanol ヱヶΓ 
solutions. For antigen retrieval, the sections were placed in 10 mM citric acid buffer (pH 6.0) ヱΑヰ 
and incubated in a pre-heated water-bath maintained at 95°C for 15 min. Endogenous ヱΑヱ 
peroxidase activity was quenched by treatment with methanol containing 3% hydrogen ヱΑヲ 
peroxide for 30 m. Sections were then incubated in diluted blocking serum for 30 m, ヱΑン 
followed by incubation overnight at 4°C with ErbB4 antibody (1:100 dilution). For human ヱΑヴ 
and mouse kidney sections, a peroxidase-conjugated secondary antibody was employed and ヱΑヵ 
peroxidase activity was visualised using a substrate solution of diaminobenzidine (DAB) ヱΑヶ 
containing 0.03% hydrogen peroxide. Negative control sections were processed with ヱΑΑ 
omission of the primary antibody and a non-immune IgG. All sections were counterstained in ヱΑΒ 
haematoxylin. ヱΑΓ 
 ヱΒヰ 
Luciferase Reporter Assay ヱΒヱ 
A 428bp fragment of the 3’UTR of ErbB4 containing a predicted mir-193b-3p seed sequence ヱΒヲ 
was amplified from RNA extracted from HEK-293 cells by PCR using the following primers:  ヱΒン 
Forward:  GGTCGTGAGCTCCACACCTGCTCCAATTTCCCC  ヱΒヴ 
Reverse:  CTCGTACTCGAGATGCACACATCAGTTCCTGC ヱΒヵ 
ヱヰ 
 
Following reverse transcription, ErbB4 3’UTR cDNA was subcloned into a pmirGLO ヱΒヶ 
reporter plasmid (Promega). The predicted mir-193b-3p seed sequence was mutated using the ヱΒΑ 
following primers according to the Stratagene site-directed mutagenesis protocol: ヱΒΒ 
Forward: CTTCCTTCTACCCCAAGGCGTCTCGTTTTGACACTTCCCAG ヱΒΓ 
Reverse:  CTGGGAAGTGTCAAAACGAAGACGCCTTGGGGTAGAAGGAAG ヱΓヰ 
For the luciferase assay, HEK293 cells were plated into a 96-well plate at 25,000 cells / well ヱΓヱ 
the day before transfection. For 5 replicates, 1.5µL of Lipofectamine 2000 reagent was mixed ヱΓヲ 
to 50µL of OptiMEM medium and 375µg of pcDNA 3.1 + 125ng pmirGLO vector together ヱΓン 
with negative control miRNA or a mir-193b-3p mimic at a final concentration of 25 or 50 ヱΓヴ 
nM. 24 h after transfection, the luciferase/renilla signals ratios were measured using the Dual ヱΓヵ 
Luciferase Reporter Assay from Promega. 100 µL of Passive Lysis Buffer was added directly ヱΓヶ 
into the wells to lysate the cells and 50 µL from each well were used for signal detection with ヱΓΑ 
a Perkin Elmer luminometer. ヱΓΒ 
 ヱΓΓ 
ErbB4 functional inhibition assays ヲヰヰ 
Control and ADPKD cells were plated at 5000 cells/well in a 96well plate. Cells were ヲヰヱ 
incubated with a pan-ErbB inhibitor including to ErbB4, JNJ 28871063 hydrochloride ヲヰヲ 
(Tocris, USA) for 24 h, an inhibitory ErbB4 antibody (clone H.72.8, Millipore, USA) or non-ヲヰン 
immune control rabbit antibody for 72 h. To test the effect of the ErbB4 ligand NRG-1, cells ヲヰヴ 
were serum starved for 24 h prior to incubation with 100 ng/ml NRG-1 (Cell Signalling, ヲヰヵ 
USA) for 72 h. Following the indicated treatment, cell proliferation was measured using a ヲヰヶ 





Matrigel 3D cyst assays ヲヱヰ 
OX161 cells (1x105/well) were mixed with 70 µl Matrigel (Becton Dickinson, UK), plated ヲヱヱ 
into 96 well plates in triplicate and incubated for 30 m at 37°C to allow the gel to set. Cells ヲヱヲ 
were cultured for 12 d in the presence or absence of 100 ng/ml NRG-1 or HB-EGF. Media ヲヱン 
was replaced every 2 d. The average cyst area was calculated by measuring cyst areas in ヲヱヴ 
individual wells on days 4, 7 and 12. At least 65 cysts were measured in triplicate wells at ヲヱヵ 
each time-point.  ヲヱヶ 
  ヲヱΑ 
Patient recruitment ヲヱΒ 
All participants gave their signed informed consent at the time of recruitment.  ADPKD ヲヱΓ 
patients were recruited through the Sheffield Kidney Institute and healthy normal volunteers ヲヲヰ 
were recruited from laboratory staff. Ethical approval for this study was obtained from the ヲヲヱ 
National Research Ethics Service Committee Yorkshire & The Humber - Bradford ヲヲヲ 
(REC12/YH/0297). Following collection, urine samples were centrifuged at 1000g for 10 ヲヲン 
min at 4oC.  Cell pellets were discarded and cell free supernatants stored at -80oC until further ヲヲヴ 
analysis.  ヲヲヵ 
 ヲヲヶ 
Isolation of Urinary Extracellular Vesicles ヲヲΑ 
Urinary extracellular vesicles (UEVs) or exosomes were isolated by differential ヲヲΒ 
centrifugation as previously reported (25). In brief, 10 ml of urine was initially centrifuged at ヲヲΓ 
17000g for 15 min. The supernatant was retained and the pellet resuspended in 200 µl ヲンヰ 
ヱヲ 
 
isolation buffer (250 mM Sucrose, 10 mM Triethanolamine pH7.6, 50 µl of DDT) to reduce ヲンヱ 
the highly abundant Tamm-Horsfall protein.  Following incubation at room temperature for 5 ヲンヲ 
min, the sample was briefly vortexed and centrifuged again at 17,000g for 15 min. This ヲンン 
supernatant was then combined with the initial supernatant and centrifuged once more at ヲンヴ 
170000 g for 150 min. The final pellet was re-suspended in 50 µl lysis buffer (50 mM Tris ヲンヵ 
pH 7.4, 150 mM sodium chloride, 1% Triton X-100, 1% sodium-deoxycholic acid and ヲンヶ 
protease inhibitors) on ice for 1 h (3). A protein assay was carried out to normalise protein ヲンΑ 
concentration prior to SDS-PAGE. ヲンΒ 
 ヲンΓ 
Electron Microscopy ヲヴヰ 
Electron microscopy was carried out to visualize the morphology of the UEVS isolated. ヲヴヱ 
Briefly, the pellet isolated was first resuspended in 50 µl PBS and a small drop of this ヲヴヲ 
mixture was deposited on 200-mesh nickel grids.  Negative staining of the mesh was carried ヲヴン 
out using heavy metal salt (0.5 % Uranium).  After drying, the nickel grids were visualized ヲヴヴ 
using a Philips electron microscope 400 operated at 80 KV. ヲヴヵ 
 ヲヴヶ 
Statistical Analysis ヲヴΑ 
Data are presented as mean values ± SEM. Student's t test or ANOVA were used for ヲヴΒ 
statistical analysis with a p value of <0.05 indicating statistical significance. The degree of ヲヴΓ 
significance as determined by GraphPad Prism software is denoted by the following asterisks: ヲヵヰ 




Parallel mRNA/miRNA expression microarray profiling in ADPKD cell lines ヲヵン 
A parallel mRNA and miRNA expression microarray was performed to identify differential ヲヵヴ 
changes in mRNA/miRNA expression levels in ADPKD cells compared to non-ADPKD ヲヵヵ 
controls. We then used this information to identify predicted mRNA/miRNA interactions ヲヵヶ 
which could contribute to ADPKD pathogenesis (Fig 1A). The expression of 1515 genes was ヲヵΑ 
significantly altered between control and ADPKD cell lines by more than 2 fold and 5 ヲヵΒ 
miRNAs were significantly altered. In total, 447 genes were significantly up-regulated (Fig ヲヵΓ 
2A) and 1068 genes (Fig 2B) significantly down-regulated in ADPKD cells. All the ヲヶヰ 
significantly altered miRNAs were down-regulated in ADPKD cells (Fig 2C). These ヲヶヱ 
miRNAs in turn were predicted to target 5721 genes (TargetScan algorithm) of which 390 ヲヶヲ 
genes were differentially expressed in the parallel mRNA microarray. Functional enrichment ヲヶン 
analysis of differentially expressed genes (>2 fold) in ADPKD was carried out using Panther ヲヶヴ 
pathway analysis software (http://www.pantherdb.org/). A total of 22 signalling pathways ヲヶヵ 
were significantly enriched from the list of genes upregulated in ADPKD whereas 8 ヲヶヶ 
pathways were significantly enriched from the list of genes downregulated in ADPKD (Fig ヲヶΑ 
1B). These included pathways reported to be associated with ADPKD including cadherin, ヲヶΒ 
EGF receptor (3.38 fold enrichment), Wnt and G protein signalling. Of the ErbB receptors, ヲヶΓ 
the only receptor showing significant differential expression was ErbB4 (~40-fold). ヲΑヰ 
 ヲΑヱ 
Validation of an interaction between mir-193b-3p and ErbB4 mRNA ヲΑヲ 
The differential increase in ErbB4 expression was first confirmed by Taqman qPCR, showing ヲΑン 
a mean 10-fold increase in ADPKD compared to control cells (Fig 3A). We noted that of the ヲΑヴ 
ヱヴ 
 
5 differentially expressed miRNA identified, mir-193b-3p was predicted to regulate ErbB4, ヲΑヵ 
this also being the highest ranked gene identified by a TargetScan prediction algorithm ヲΑヶ 
(http://www.targetscan.org/, Release 6.2) of 30 predicted targets (Fig 2D). Consistent with ヲΑΑ 
these predictions, multiple independent miRNA target prediction algorithms (DIANAmT, ヲΑΒ 
miRanda, miRDB, miRWalk, RNAhybrid, Targetscan and PICTAR5) identified two ヲΑΓ 
potential mir-193b-3p binding sites within the 3’UTR of ErbB4. ヲΒヰ 
We next validated the reduction of array mir-193b-3p expression in ADPKD cells by Taqman ヲΒヱ 
qPCR showing a 0.5 fold decrease (Fig 3B). To provide direct evidence of a functional ヲΒヲ 
interaction between mir-193b-3p and ErbB4 mRNA, we generated a luciferase reporter ヲΒン 
plasmid (pmirGLO) containing a fragment of the ErbB4 3’UTR and mutated the predicted ヲΒヴ 
mir-193b-3p seed sequence in a second reporter construct (Fig 3C). Co-expression of a mir-ヲΒヵ 
193b-3p miRNA mimic significantly reduced luciferase activity in the wild-type but had no ヲΒヶ 
effect on the mutated sequence (Fig 3D). Finally, expression of the mir-193b-3p mimic in the ヲΒΑ 
ADPKD cell line (OX161) resulted in a significant reduction in endogenous ErbB4 mRNA ヲΒΒ 
(Fig 3E) and ErbB4 protein (Fig 3F). These results provide the first evidence that ErbB4 ヲΒΓ 
mRNA is potentially a target of mir-193b-3p. ヲΓヰ 
 ヲΓヱ 
ErbB4 is over-expressed in ADPKD cell lines as two distinct isoforms  ヲΓヲ 
By immunoblotting, we confirmed that full-length ErbB4 protein were increased in all four ヲΓン 
ADPKD cell lines tested, being almost undetectable in control cells (Fig 4A). The ヲΓヴ 
ERBB4 gene however is known to undergo alternative splicing generating several isoforms ヲΓヵ 
differing in their N-termini or C-termini (Fig 4B). For instance, the two CYT isoforms differ ヲΓヶ 
in a stretch of 16 amino acids in the C-terminus encoded by a single exon (CYT-1) that is ヲΓΑ 
absent in CYT-2. This structural difference contributes to differential subcellular targeting ヲΓΒ 
ヱヵ 
 
and even antagonistic functional responses mediated by the two CYT isoforms (40). Apart ヲΓΓ 
from the CYT isoforms, tissue-specific alternative splicing can generate JM-a and JM-b ンヰヰ 
isoforms differing in their extracellular juxta-membrane (JM) domain and function (6).  ンヰヱ 
To investigate the possibility of an isoform switch in ADPKD, RT-PCR was carried out using ンヰヲ 
specific primers flanking the variable regions using cDNA isolated from OX161 cells (Fig ンヰン 
4B). As a positive control, we used a JM-a/CYT-1 plasmid. For the JM region, the expected ンヰヴ 
sizes were 0.375kb (JM-a) and 0.345kb (JM-b) respectively. A single band corresponding to ンヰヵ 
JM-a (0.375kb) was detected with no evidence of JM-b (0.345kb) (Fig 4C). Similar analysis ンヰヶ 
using primers flanking the cytoplasmic site revealed that both CYT-1 and CYT-2 isoforms ンヰΑ 
were expressed, with a higher abundance of CYT-1. Primers designed to a conserved ErbB4 ンヰΒ 
motif identified the same control band in both samples. Our results reveal the presence of two ンヰΓ 
isoforms (JM-a/CYT-1 and JM-a/CYT-2) in normal and ADPKD cells with no evidence of ンヱヰ 
an isoform switch (Fig 4D). ンヱヱ 
 ンヱヲ 
Nuclear ErbB4 expression is increased in human ADPKD kidneys and in a Pkd1 mouse ンヱン 
model  ンヱヴ 
The expression of ErbB4 was increased in cyst lining epithelial cells of human ADPKD ンヱヵ 
kidney sections compared to control kidney tissue by immunohistochemistry (Fig 4E). ンヱヶ 
Significantly elevated nuclear localisation of ErbB4 was observed in ErbB4 positive cysts ンヱΑ 
(black arrows) indicating increased levels of ErbB4 protein and C-terminal cleavage (Fig 4E, ンヱΒ 
F). We next analysed ErbB4 expression in a previously reported inducible kidney-specific ンヱΓ 
Pkd1 mutant mouse model (14). Following induction with tamoxifen at PN40 these animals ンヲヰ 
slowly develop a cystic phenotype with large cysts becoming apparent 4 months after ンヲヱ 
tamoxifen induction. In agreement with the human studies, there was a significant increase in ンヲヲ 
ヱヶ 
 
ErbB4 mRNA expression in Cre;Pkd1del2–11,lox  mice induced with Tamoxifen at 4 months ンヲン 
(Fig 4G). Similarly, ErbB4 staining was increased in cyst lining epithelial cells of kidney ンヲヴ 
sections. The number of ErbB4 positive cysts increased following Pkd1 deletion with the ンヲヵ 
strongest staining at 4 months after tamoxifen induction.  (Fig 4H) In agreement elevated ンヲヶ 
nuclear localisation in ErbB4 positive cysts was significant from 2 months after induction ンヲΑ 
(Fig 4I). In both human and mouse tissue sections a minority of cysts (~20%) showed no ンヲΒ 
detectable ErbB4 staining although it was not possible to distinguish these from positive ンヲΓ 
stained cysts in terms of size or time following induction. At 4 months, a significant decrease ンンヰ 
in mir-193b-3p mRNA was detectable in Cre;Pkd1del2–11,lox kidneys (Fig 4J).  ンンヱ 
 ンンヲ 
Increased expression of cleaved ErbB4 and decreased expression of mir-193b-3p in ンンン 
human ADPKD urinary extracellular vesicles ンンヴ 
To confirm that these changes also occurred in vivo, we isolated urinary extracellular vesicles ンンヵ 
(UEV) from healthy volunteers (n=12) and ADPKD patients with early (eGFR ンンヶ 
>60ml/min/1.73m2, n=16) or late disease (eGFR <60ml/min/1.73m2, n=16) using an ンンΑ 
established protocol (25). Electron microscopy confirmed the presence of multiple (<100nm) ンンΒ 
vesicles in the pelleted fraction (Fig 5A). The exosome-specific protein TSG-101 was ンンΓ 
restricted to the pellet and there was clear expression of aquaporin-2 (AQP2) in both cell-free ンヴヰ 
urine and the pellet indicating the origin of some vesicles from collecting ducts (Fig 5B). ンヴヱ 
An ErbB4 positive band was detected at 80 kDa in UEVs, corresponding to the known C-ンヴヲ 
terminal intracellular domain (ICD) generated by け-secretase mediated cleavage (Fig 5C). A ンヴン 
minor band at 50 kDa was also observed which could correspond to proteolytic degradation ンヴヴ 
or represent a non-specific band. Expression of the 80kDa band was significantly increased in ンヴヵ 
the UEVs of ADPKD patients compared to healthy controls particularly in patients with late ンヴヶ 
ヱΑ 
 
disease as defined by baseline eGFR (Fig 5D). ErbB4 expression also correlated significantly ンヴΑ 
with the rate of decline in eGFR and outperformed mean kidney length (MKL) measured by ンヴΒ 
ultrasound (Fig 5E). In combination, ErbB4 and MKL were additive in ROC analysis, ンヴΓ 
accounting for 0.816 of AUC (p=0.002). ンヵヰ 
 ンヵヱ 
Increased ligand dependent proliferation signalling and cyst growth in ADPKD cells  ンヵヲ 
A total of 11 ligands have been reported to bind to members of the EGF receptor family. Of ンヵン 
these, several have been shown to activate ErbB4 including the neuregulins (NRG1-4) and ンヵヴ 
HB-EGF (27). However, ErbB4 activation can stimulate or inhibit proliferation in different ンヵヵ 
cells, possibly due to differential expression of ErbB4 isoforms (37, 40). ンヵヶ 
To determine the functional consequence of ErbB4 overexpression in ADPKD cells, we first ンヵΑ 
studied their response to NRG-1. A significant increase in NRG-1 mediated proliferation was ンヵΒ 
seen in the PKD1 cell lines with almost no effect in control cells (Fig 6A). This was mirrored ンヵΓ 
by significant increases in phosphorylated ErbB4 (pErbB4) in response to NRG-1 (Fig 6B). ンヶヰ 
Since the OX161 line showed the greatest response to NRG-1, this line was used for further ンヶヱ 
experiments.  ンヶヲ 
The JM-a isoforms of ErbB4 are known to undergo two step-wise proteolytic cleavage events ンヶン 
when activated, generating a shed N-terminal ectodomain (110kDa) by Tumour Necrosis ンヶヴ 
Factor Alpha Converting Enzyme (TACE) cleavage and a soluble intracellular C-terminal ンヶヵ 
domain (80kDa) by the action of γ-secretase (17).  Several downstream signalling pathways ンヶヶ 
are known to be activated including the PI3K/AKT pathway (cell survival), STAT 5 ンヶΑ 
(mammary development), Ras/ERK1/2 and PLCけ pathways (cell proliferation). Accordingly, ンヶΒ 
ヱΒ 
 
a significantly greater increase in pERK and pAKT was observed in ADPKD (OX161) cells ンヶΓ 
in response to NRG-1 compared to control (UCL93) cells (Fig 6C).  ンΑヰ 
A small single centre study recently reported that urinary HB-EGF excretion was increased in ンΑヱ 
a cohort of ADPKD patients and showed a positive correlation with more advanced disease ie ンΑヲ 
lower GFR and higher total kidney volumes (10). In contrast, urinary EGF and TGF-α levels ンΑン 
decreased with increasing disease severity. Incubation with HB-EGF, similar to NRG-1, was ンΑヴ 
associated with an increase in phosphorylated ErbB4 in ADPKD cells (OX161) suggesting a ンΑヵ 
potential role in activating ErbB4 in ADPKD cells (Fig 6D). The effect of both ErbB4 ンΑヶ 
ligands on cyst growth was therefore studied in 3D cyst assays. OX161 cells spontaneously ンΑΑ 
form cyst-like structures with well-developed lumen when cultured in matrigel. Both NRG-1 ンΑΒ 
and HB-EGF significantly increased cyst growth in OX161 cells as measured by total cyst ンΑΓ 
area in 3D cyst assays (Fig 6E). These results confirm that ligand-activated ErbB4 signalling ンΒヰ 
is likely to be a pathogenic factor in ADPKD cyst expansion, by promoting cell survival and ンΒヱ 
stimulating cell proliferation. ンΒヲ 
 ンΒン 
Inhibition of ErbB4 reduces proliferation in ADPKD cells ンΒヴ 
Over-expression of ErbB4 in control (UCL93) cells significantly increased basal cell ンΒヵ 
proliferation showing that increasing ErbB4 expression alone was sufficient to induce a pro-ンΒヶ 
proliferative phenotype (Fig 7A). Conversely, siRNA knockdown of ErbB4 in OX161 cells ンΒΑ 
inhibited cell proliferation compared to control siRNA treated cells (Fig 7B, C).  ンΒΒ 
A pan-ErbB inhibitor (JNJ 28871063) which inhibits ErbB1, ErbB2 and ErbB4 (IC50 21-38 ンΒΓ 
nM) (7) reduced proliferation of OX161 cells but had no effect on UCL93 cells at the same ンΓヰ 
ヱΓ 
 
doses (Fig 7D). These results are consistent with the specificity of JNJ 28871063 on ErbB-ンΓヱ 
driven cancer cell lines but its lack of effect in non-ErbB lines (7). ンΓヲ 
Although ErbB1, ErbB2 and ErbB3 were not differentially expressed in the ADPKD cells, ンΓン 
we decided to utilise an ErbB4-specific inhibitory antibody to isolate an ErbB4 specific role ンΓヴ 
in these cells (12, 29, 39). ErbB4 selective blockade reduced basal proliferation in OX161 ンΓヵ 
cells to that seen in UCL93 control cells (Fig 7E) whereas an irrelevant IgG control antibody ンΓヶ 
had no effect (Fig 7F). These results demonstrate that ErbB4 activation could contribute to ンΓΑ 
the increased proliferation rate of ADPKD cells, probably through the action of endogenous ンΓΒ 




In this paper, we report the identification of ErbB4 as a potential new biomarker of disease ヴヰヱ 
activity and a new therapeutic target in ADPKD. Parallel discovery microarray profiling in a ヴヰヲ 
panel of human ADPKD cell lines previously shown to express germline and somatic ヴヰン 
mutations in PKD1 but not PKD2 (24) identified a total of 1513 differentially expressed ヴヰヴ 
genes in ADPKD cells mapping to several pathways previously implicated in ADPKD. We ヴヰヵ 
also identified 5 miRNAs that were significantly down regulated in ADPKD cells. ヴヰヶ 
The EGF/ErbB receptor family has been previously implicated in experimental models of ヴヰΑ 
ADPKD (11). The ErbB receptor family has four members: EGFR/ErbB1, ErbB2/HER2/neu, ヴヰΒ 
ErbB3/HER3 and ErbB4/HER4 which belong to the receptor tyrosine kinase superfamily. A ヴヰΓ 
total of 11 putative ligands with different receptor selectivity to the ErbB receptors have been ヴヱヰ 
reported, with the exception of ErbB2 (27). The complexity of EGF/ErbB signalling is further ヴヱヱ 
compounded by the formation of different homo- and heterodimers and the existence of ヴヱヲ 
multiple splice forms (especially for ErbB4). ヴヱン 
The role of EGF/ErbB signalling in ADPKD pathogenesis has attracted attention due to the ヴヱヴ 
hyperproliferative phenotype that characterises ADPKD (1). However, inhibition of EGF ヴヱヵ 
signalling has yielded conflicting results in different experimental models. For instance, an ヴヱヶ 
EGFR and ErbB2 antagonist reduced cystic disease in the Han:SPRD rat and bpk mouse ヴヱΑ 
models but had a detrimental effect in the Pck rat (26, 32, 34, 35). Nonetheless, the ヴヱΒ 
physiological importance of the EGF receptor during kidney development, repair and tubular ヴヱΓ 
physiology could make this a difficult drug target for ADPKD. ヴヲヰ 
We decided to focus our study on ErbB4 for a number of reasons. In murine PKD disease ヴヲヱ 
models, renal ErbB4 expression has been shown to be increased (bpk, cpk) (19, 42). ErbB4 ヴヲヲ 
plays a key role during nephrogenesis being induced in the earliest murine tubular structures ヴヲン 
ヲヱ 
 
by E14.5 and later in the collecting ducts (37). ErbB4 null mice die by E11 prior to ヴヲヴ 
nephrogenesis due to defective heart development (9) but ErbB4 knockout mice rescued with ヴヲヵ 
a cardiac myosin-promoter driven ErbB4 transgene have defective mammary gland and ヴヲヶ 
neuronal abnormalities but no reported kidney phenotype and display a normal lifespan (33). ヴヲΑ 
Consistent with a major role during development, conditional deletion (Pax8-Cre) of ErbB4 ヴヲΒ 
affecting both renal ErbB4 isoforms (JMa-CYT-1, JMa-CYT-2) from E11.5 altered normal ヴヲΓ 
tubular diameter, cell number and differentiation (37). Conversely, transgenic expression of ヴンヰ 
JMa-CYT-2 in the kidney from E11.5 resulted in cortical cysts, tubular proliferation and ヴンヱ 
lumen dilatation (37). Unexpectedly, another group reported that deletion of ErbB4 ヴンヲ 
significantly worsened the cystic phenotype of cpk mice, a recessive model of PKD (42). One ヴンン 
possible explanation for this discrepancy is that both major ErbB4 isoforms were deleted in ヴンヴ 
this study. While deletion of JMa-CYT-2 should be protective (see below), deletion of the ヴンヵ 
JMa-CYT-1 isoform could enhance cystogenesis by removing an inhibitory brake on cell ヴンヶ 
proliferation; the differential expression of each ErbB4 isoform in the kidneys of cpk mice ヴンΑ 
was not reported. This imbalance created by deleting both ERbB4 isoforms could have ヴンΒ 
resulted in the surprising results observed in cpk/ErbB4 null mice. Formal testing of these ヴンΓ 
possibilities in orthologous models by chemical or genetic manipulation will be required to ヴヴヰ 
obtain a definitive answer relevant to ADPKD. ヴヴヱ 
We observed a consistent upregulation of ErbB4 expression in human and mouse disease ヴヴヲ 
models, both in vitro and in vivo. In addition, we report for the first time that ErbB4 is a ヴヴン 
direct target for mir-193b-3p. The increase in ErbB4 mRNA occurs early in disease (2 ヴヴヴ 
months in Pkd1 conditional mice, Fig 4G) and is likely to involve increased gene ヴヴヵ 
transcription in view of the magnitude of ErbB4 elevation (10-fold) observed in cells. At a ヴヴヶ 
later stage of disease, it is probable that the reduction in mir-193b-3p expression also ヴヴΑ 
contributes to a post-transcriptional increase in ErbB4 mRNA levels (Fig 4G, J).  ヴヴΒ 
ヲヲ 
 
In the kidney, ErbB4 is expressed predominantly as the isoforms JM-a/CYT-1 and JM-ヴヴΓ 
a/CYT-2, with possibly more medullary expression of JM-a/CYT-2 (37, 44). Both isoforms ヴヵヰ 
undergo sequential proteolytic cleavage to generate a soluble intracellular domain (ICD) that ヴヵヱ 
can translocate to the nucleus to regulate gene transcription. The CYT-1 isoform contains a ヴヵヲ 
16 aa sequence which is lacking in the CYT-2 isoform, enabling CYT-1 to couple to PI3K. ヴヵン 
However, levels of kinase activity, protein stability and nuclear accumulation are greater for ヴヵヴ 
the CYT-2 ICD than the CYT-1 ICD (30, 43). CYT-1 ICD inhibits cell proliferation, ヴヵヵ 
undergoes ubiquitination but promotes cell differentiation whereas the opposite is true for the ヴヵヶ 
CYT-2 ICD (18, 31, 38, 40). Both isoforms were similarly expressed in control and ADPKD ヴヵΑ 
cells with a slightly greater expression of CYT-1.  ヴヵΒ 
The increase in ErbB4 expression was also associated with increased ligand-activated ヴヵΓ 
signalling. Addition of two ErbB4 ligands, NRG-1 and HB-EGF, was associated with ヴヶヰ 
increased ErbB4 phosphorylation, downstream activation of pERK and pAKT pathways, ヴヶヱ 
increased proliferation and cyst formation in ADPKD cells. Conversely, blocking ヴヶヲ 
endogenous ErbB4 in cystic cells using siRNA, a kinase inhibitor (JNJ288) or an anti-ヴヶン 
functional antibody (H.72.8) reduced cell proliferation to that of untreated controls. These ヴヶヴ 
findings were confirmed by evidence of increased ErbB4 activation in vivo. Cystic human ヴヶヵ 
and murine kidney sections showed increased nuclear expression of C-terminal ErbB4. ヴヶヶ 
Finally, we detected increased levels of cleaved C-terminal ErbB4 in human ADPKD UEVs ヴヶΑ 
compared to healthy controls. ErbB4 expression was significantly raised in patients with ヴヶΒ 
reduced kidney function (eGFR>60ml/min/1.73m2) and in ROC analysis, was significantly ヴヶΓ 
correlated with a more rapid rate of eGFR decline (>3ml/min/pa), outperforming ultrasound-ヴΑヰ 
measured mean kidney length. These findings suggest that ErbB4 signalling closely parallels ヴΑヱ 
disease activity and could represent a prognostic biomarker of disease progression.  ヴΑヲ 
ヲン 
 
Our results point to the possibility of targeting ErbB4 to retard cyst growth and disease ヴΑン 
progression in ADPKD. This could be done at several levels or in combination eg blocking ヴΑヴ 
the ligands such as NRG-1 or HB-EGF, targeting ErbB4 itself through anti-functional ヴΑヵ 
antibodies (12, 29, 39), reducing its expression through mir-193b-3p mimics (5, 28, 36, 41) or ヴΑヶ 
through inhibiting downstream kinase activity with selective small molecule inhibitors. ヴΑΑ 
Previous studies have detected a significant increase in NRG-1 (2, 23) or HB-EGF (13) in ヴΑΒ 
Pkd1
 cystic kidneys and increased urinary HB-EGF has been detected in human ADPKD ヴΑΓ 
(10). Of interest, it was reported in the same study that treatment with the vasopressin V2 ヴΒヰ 
receptor antagonist (V2RA), tolvaptan, was associated with a significant increase in urinary ヴΒヱ 
HB-EGF (10). This simultaneous upregulation of HB-EGF could mean that treatment with ヴΒヲ 
tolvaptan is less effective than would be predicted from its effect on cAMP production. ヴΒン 
Therefore, combining a V2RA with a therapy which blocks ErbB4 signalling could be ヴΒヴ 
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Figure Legends ヶンΓ 
Fig 1. Parallel mRNA/miRNA expression microarray profiling in ADPKD cell lines ヶヴヰ 
(A) Systematic workflow used to analyse parallel mRNA/miRNA changes between control ヶヴヱ 
(n=2) and ADPKD derived cystic cell lines (n=4). (B) Pathway enrichment analysis was ヶヴヲ 
carried out on the 1515 significantly altered (p<0.05 by TTest) genes which were up or down ヶヴン 
regulated by >2 fold in ADPKD cell lines using the Panther classification system ヶヴヴ 
(http://www.pantherdb.org/). ヶヴヵ 
Fig 2. Differential expression of mRNAs and miRNAs in ADPKD cystic cell lines  ヶヴヶ 
(A). Differential expression of the top 30 genes up-regulated in ADPKD cell lines expressed ヶヴΑ 
as a heatmap. The heatmap was produced by clustering the data matrix of the top 30 genes in ヶヴΒ 
GenespringX (Agilent, USA). Analysis of differential expression by TTest was carried out ヶヴΓ 
using Agilent GeneSpring GX software and p-values >0.05 were defined as significant. (B). ヶヵヰ 
Differential expression of the top 30 genes down-regulated in ADPKD cell lines expressed as ヶヵヱ 
a heatmap. The heatmap was produced by clustering the data matrix of the top 30 genes in ヶヵヲ 
GenespringX (Agilent, USA). Analysis of differential expression by TTest was carried out ヶヵン 
using Agilent GeneSpring GX software and p-values >0.05 were defined as significant. (C). ヶヵヴ 
Differential expression of the 5 significantly altered miRNAs in ADPKD cell lines expressed ヶヵヵ 
as a heatmap. The heatmap was produced by clustering the data matrix of the altered ヶヵヶ 
miRNAs in GenespringX (Agilent, USA). Analysis of differential expression by TTest was ヶヵΑ 
carried out using Agilent GeneSpring GX software and p-values >0.05 were defined as ヶヵΒ 
significant. (D). Differential expression of the top 30 genes predicted to be targets of mir-ヶヵΓ 
193b-3p by Targetscan algorithm which were up-regulated in ADPKD cell lines expressed as ヶヶヰ 
a heatmap. The heatmap was produced by clustering the data matrix of the top 30 genes in ヶヶヱ 
GenespringX (Agilent, USA). ヶヶヲ 
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Fig 3. ErbB4 expression is increased in ADPKD cells and is a direct target for mir-193b-ヶヶン 
3p ヶヶヴ 
(A) Taqman qPCR assays for ErbB4 show a significant increase in expression of transcript in ヶヶヵ 
ADPKD derived cell lines (n=4) compared to control cell lines (n=4) representing a 10-fold ヶヶヶ 
change relative to control. (B) Taqman qPCR assays for mir-193b-3p show a significant ヶヶΑ 
reduction in expression of transcript in ADPKD derived cell lines (n=4) compared to control ヶヶΒ 
cell lines (n=4) representing a fold change of 0.5066 relative to control. (C) Identification of ヶヶΓ 
the sequence within the 3’UTR of ErbB4 between nt91-98 recognised by the mir-193b-3p ヶΑヰ 
seed sequence CCGGUCA. The 3 base pairs in ErbB4 predicted to disrupt binding of mir-ヶΑヱ 
193b-3p and which were mutated are shown in italics. (D) ErbB4 (pmirGLO ErbB4) or ヶΑヲ 
mutated ErbB4 3’UTR (pmirGLO mErbB4) was cloned into a pmirGLO luciferase reporter ヶΑン 
vector and transfected into HEK-293 cells. HEK-293 cells were co-transfected with control ヶΑヴ 
or mir-193b-3p miRNA mimics at 20 and 50nM. A significant reduction in luciferase activity ヶΑヵ 
was seen in cells transfected with ErbB4 3’UTR and a mir-193b-3p mimic but not in cells ヶΑヶ 
transfected with mutated ErbB4 3’UTR. A negative non-targeting miRNA control mimic had ヶΑΑ 
no effect on luciferase activity. (E) Taqman qPCR assays for ErbB4 show a significant ヶΑΒ 
decrease in expression of the endogenous mRNA transcript in OX161 cells when transfected ヶΑΓ 
with 50nM mir-193b mimic (n=3) relative to cells transfected with 50 nM scrambled negative ヶΒヰ 
control mimic (n=3) representing a fold change of 0.6207 relative to control. (F)  ヶΒヱ 
Transfection of HEK-293 cells with a mir-193b-3p mimic (50 nM) caused a significant ヶΒヲ 
decrease in ErbB4 protein expression as detected with a specific ErbB4 antibody. The blot ヶΒン 
was reprobed for calnexin to confirm equal loading. A significant decrease in ErbB4/calnexin ヶΒヴ 
ratio (40.5% decrease compared to negative control miRNA) was seen in cells transfected ヶΒヵ 




Fig 4. The expression and activation of two ErbB4 isoforms is increased in ADPKD ヶΒΒ 
cystic cells and kidney tissue ヶΒΓ 
(A) Expression of full-length uncleaved ErbB4 (180 kDa) was increased in ADPKD cells ヶΓヰ 
compared to controls. Blots were reprobed for calnexin to confirm equal loading. The ヶΓヱ 
ErbB4/calnexin ratio in ADPKD cells was significantly increased compared to controls. Data ヶΓヲ 
is presented as an average of 3 separate repeat experiments. (B). Schematic diagram of ErbB4 ヶΓン 
depicting the position of primers used to amplify domains present in different isoforms. (C) ヶΓヴ 
Isoform specific primers were designed to amplify endogenous JM-a, CYT-1/2 or all ErbB4 ヶΓヵ 
from OX161 mRNA by RT-PCR. A plasmid expressing the JM-a CYT-1 isoform of ErbB4 ヶΓヶ 
(pcDNA3.1-ErbB4) was used as a positive control template. Two isoforms, JM-a CYT-1 and ヶΓΑ 
JM-a CYT-2, were found to be present in OX161. (D) The two ErbB4 isoforms JM-a CYT-1 ヶΓΒ 
and JM-a CYT-2 were similarly expressed in all normal and ADPKD cell lines tested. (E) ヶΓΓ 
Increased expression of ErbB4 was observed in cyst lining epithelial cells of kidney tissue Αヰヰ 
sections from patients with ADPKD (n=7) compared to controls (n=3). Nuclear localisation Αヰヱ 
of ErbB4 was detected in ErbB4 positive cysts (black arrows) indicating ErbB4 cleavage and Αヰヲ 
activation of gene transcription. (F) Nuclear ErbB4 expression was significantly increased in Αヰン 
ErbB4 positive cysts in ADPKD kidneys compared to controls.. *** P<0.001. (G) ErbB4 Αヰヴ 
mRNA was significantly increased in kidneys derived from Cre;Pkd1del2–11,lox mice at 4 Αヰヵ 
months after Tamoxifen compared to untreated control animals (n=4-5) as detected by Αヰヶ 
Taqman qPCR assays. (H) Increased expression of ErbB4 was seen in the cyst lining ΑヰΑ 
epithelial cells of cystic kidneys from Cre;Pkd1del2–11,lox mice 3 and 4 month after tamoxifen ΑヰΒ 
induction compared to control un-induced animals (n=6 each). Nuclear localisation of ErbB4 ΑヰΓ 
was observed in ErbB4 positive cysts (black arrows) indicating ErbB4 cleavage and Αヱヰ 
activation of gene transcription. (I) Nuclear ErbB4 expression was significantly increased in Αヱヱ 
ErbB4 positive cysts in Cre;Pkd1del2–11,lox mice compared to control mice 2, 3 and 4 month Αヱヲ 
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after treatment with tamoxifen *** P<0.001. (J) mir193b-3p miRNA was significantly Αヱン 
decreased in kidneys derived from Cre;Pkd1del2–11,lox mice at 4 months after Tamoxifen Αヱヴ 
compared to untreated control animals (n=4-5) as detected by Taqman qPCR. Αヱヵ 
 Αヱヶ 
Fig 5. Increased ErbB4 in urinary extracellular vesicles from ADPKD patients ΑヱΑ 
correlates with renal disease progression. ΑヱΒ 
(A) Electron microscopy of purified urinary extracellular vesicles. Extracellular vesicles with ΑヱΓ 
a diameter <100nm can be seen (arrows) indicating successful purification of urinary Αヲヰ 
exosomes (magnification x 26000). An expanded view of a cluster of vesicles (box in A) Αヲヱ 
shows a measured diameter of 66.7nm in a typical vesicle. (B) Immunoblotting of cell free Αヲヲ 
urine, exosome preparation supernatant, concentrated cell free urine and exosome pellet. Αヲン 
Expression of TSG-101 was observed only in the exosome pellet fraction, indicating Αヲヴ 
purification of urinary exosomes. Tamm-Horsfall protein (THP) and Aquaporin-2 (AQP2) Αヲヵ 
were present in concentrated cell free urine as well as in the exosome pellet. (C) Αヲヶ 
Representative blot showing increased ErbB4 expression in ADPKD patient urine exosomes ΑヲΑ 
compared to normal controls (n=12). The arrowhead indicates an 80 kDa ErbB4 C-terminal ΑヲΒ 
cleavage product; the asterisk indicates a possible non-specific band around 50kDa. The ΑヲΓ 
exosome specific protein TSG-101 was used as a loading control. (D) A significant increase Αンヰ 
in ErbB4 expression was seen in ADPKD patient urine exosomes with an eGFR<60 (n=16) Αンヱ 
compared to controls (n=12) or ADPKD patients with an eGFR>60 (n=16). ***p<0.001, Αンヲ 
****p<0.0001. (E) ROC curves for exosome associated ErbB4 for dichotomized GFR slope Αンン 
(cut-off > or < -3 ml/min).  ErbB4 had a higher AUC than mean kidney length reflecting the Αンヴ 
ability to discriminate between patients with higher risk of progression. The AUC was Αンヵ 
significantly increased (p=0.002) when ErBB4 was combined with mean kidney length. Αンヶ 
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Fig 6. Activation of ErbB4 dependent cell proliferation, signalling and cytogenesis is ΑンΑ 
increased in ADPKD cells. ΑンΒ 
(A) Addition of the ErbB4 ligand NRG-1 (100 ng/ml) resulted in a significantly greater ΑンΓ 
increase in proliferation from baseline in ADPKD compared to control cells by a BrdU Αヴヰ 
incorporation assay. ** p<0.01, *p<0.05.  (B) NRG-1 incubation led to a much higher level Αヴヱ 
of phosphorylated ErbB4 (pErbB4) in ADPKD compared to normal controls. pErbB4 Αヴヲ 
(Tyr1118) was detected as two bands (arrowheads) representing full-length (180kDa) and C-Αヴン 
terminal cleaved (80kDa) proteins. The blot was reprobed for actin to check for loading. The Αヴヴ 
pErbB4/actin ratio in ADPKD cells was significantly higher compared to controls. Data is Αヴヵ 
presented as an average of 3 separate repeat experiments (graph in lower panel). (C) ADPKD Αヴヶ 
(OX161) cells stimulated with NRG-1 (1-100 ng/ml) for 15 min show a greater increase in ΑヴΑ 
pERK and pAKT compared to Normal (N, UCL93) cells. Basal pAKT was also noticeably ΑヴΒ 
higher in unstimulated ADPKD cells. Equal loading was confirmed by reprobing for total ΑヴΓ 
ERK or AKT. Representative blot of three experiments. The pAKT/total AKT and Αヵヰ 
pERK/total ERK ratio in ADPKD cells were significantly higher following stimulation with Αヵヱ 
10 and 100ng/ml NRG-1 compared to controls. Data is presented as an average of 3 separate Αヵヲ 
repeat experiments (graphs). (D) HB-EGF incubation (100ng/ml for 15 min) led to an Αヵン 
increase in phosphorylated ErbB4 (pErbB4) in ADPKD cells. pErbB4 (Tyr1118) was Αヵヴ 
detected as two bands representing full-length (180kDa) and C-terminal cleaved (80kDa) Αヵヵ 
proteins. The blot was reprobed for actin to check for loading. (E) OX161 cells form cysts Αヵヶ 
with visible lumen in a time dependent manner when cultured in a 3D matrix (matrigel) over ΑヵΑ 
12 days. (F) There was a significant increase in average cyst area in cells cultured with 100 ΑヵΒ 




Fig 7. ErbB4 mediates proliferation in ADPKD cell lines. Αヶヱ 
(A) Transfection of control cells (UCL93) with pcDNA3.1-ErbB4 plasmid was associated Αヶヲ 
with a significant increase in cell proliferation as measured by BrDU incorporation, Αヶン 
compared to untransfected cells or cells transfected with a pcDNA3.1 empty Αヶヴ 
vector.****p<0.0001. (B) Transfection of ADPKD cells (OX161) with specific ErbB4 Αヶヵ 
siRNA resulted in a significant reduction in ErbB4 mRNA detected by Taqman qPCR assay Αヶヶ 
representing a fold change of 0.4036 relative to scrambled control siRNA. (C) Transfection ΑヶΑ 
of OX161 cells with specific ErbB4 siRNA resulted in a significant reduction in proliferation ΑヶΒ 
compared to cells transfected with a negative, scrambled control siRNA.*p<0.05. The fold ΑヶΓ 
change reduction in ErbB4 mRNA by ErbB4 specific siRNA was detected by Taqman qPCR ΑΑヰ 
assay and showed a fold change of 0.4036 relative to scrambled control siRNA. (D) ΑΑヱ 
Incubation of cells with a pan-ErbB small molecule inhibitor (JNJ 28871063) for 24 h ΑΑヲ 
resulted in a dose-dependent decrease in cell proliferation in ADPKD (OX161) cells ΑΑン 
compared to controls. *p<0.05, **p<0.01. (E) Incubation of cells with an ErbB4 specific ΑΑヴ 
blocking antibody (H4.72.8) for 24 h led to a significant reduction in cell proliferation in ΑΑヵ 
ADPKD (OX161) cells compared to controls. *p<0.05, **p<0.01, ***p<0.001. (F) A non-ΑΑヶ 
specific control mouse IgG for 24 h had no effect on cell proliferation in ADPKD (OX161) ΑΑΑ 
cells compared to controls. ΑΑΒ 







